Mayo Clinic Proceedings Home
MCP Digital Health Home

Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials



      To synthesize more conclusive evidence on the anti-inflammatory effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).


      PubMed, Scopus, and Embase were searched from inception until March 1, 2021. We included randomized controlled trials (RCTs) that assessed the effect of ACEIs or ARBs, compared with placebo, on any of the following markers: C-reactive protein (CRP), interleukin 6 (IL-6), or tumor necrosis factor α (TNF-α). Mean changes in the levels of these markers were pooled as a weighted mean difference (WMD) with a 95% CI.


      Thirty-two RCTs (n=3489 patients) were included in the final analysis. Overall pooled analysis suggested that ACEIs significantly reduced plasma levels of CRP (WMD, −0.54 [95% CI, −0.88 to −0.21]; P=.002; I2=96%), IL-6 (WMD, −0.84 [95% CI, −1.03 to −0.64]; P<.001; I2=0%), and TNF-α (WMD, −12.75 [95% CI, −17.20 to −8.29]; P<.001; I2=99%). Moreover, ARBs showed a significant reduction only in IL-6 (WMD, −1.34 [95% CI, −2.65 to −0.04]; P=.04; I2=85%) and did not significantly affect CRP (P=.15) or TNF-α (P=.97) levels. The lowering effect of ACEIs on CRP levels remained significant with enalapril (P=.006) and perindopril (P=.01) as well as with a treatment duration of less than 24 weeks (WMD, -0.67 [95% CI, −1.07 to -0.27]; P=.001; I2=94%) and in patients with coronary artery disease (WMD, −0.75 [95% CI, −1.17 to −0.33]; P<.001; I2=96%).


      Based on this meta-analysis, ACEIs showed a beneficial lowering effect on CRP, IL-6, and TNF-α, whereas ARBs were effective as a class in reduction of IL-6 only.

      Abbreviations and Acronyms:

      ACEI (angiotensin-converting enzyme inhibitor), AngII (angiotensin II), ARB (angiotensin receptor blocker), CAD (coronary artery disease), CRP (C-reactive protein), CVD (cardiovascular disease), IL-6 (interleukin 6), RAAS (renin-angiotensin-aldosterone system), RCT (randomized controlled trial), T2DM (type 2 diabetes mellitus), TNF-α (tumor necrosis factor α), WMD (weighted mean difference)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Libby P.
        Inflammation in atherosclerosis.
        Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051
        • Pradhan A.
        Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders.
        Nutr Rev. 2007; 65: S152-S156
        • Gao B.
        • Tsukamoto H.
        Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?.
        Gastroenterology. 2016; 150: 1704-1709
        • Jayedi A.
        • Rahimi K.
        • Bautista L.E.
        • Nazarzadeh M.
        • Zargar M.S.
        • Shab-Bidar S.
        Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies.
        Heart. 2019; 105: 686-692
        • Bowker N.
        • Shah R.L.
        • Sharp S.J.
        • et al.
        Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes.
        EBioMedicine. 2020; 61: 103062
        • Festa A.
        • D’Agostino R.
        • Howard G.
        • Mykkänen L.
        • Tracy R.P.
        • Haffner S.M.
        Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).
        Circulation. 2000; 102: 42-47
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Schmieder R.E.
        • Hilgers K.F.
        • Schlaich M.P.
        • Schmidt B.M.
        Renin-angiotensin system and cardiovascular risk.
        Lancet. 2007; 369: 1208-1219
        • Brasier A.R.
        • Recinos A.
        • Eledrisi M.S.
        • Runge M.S.
        Vascular inflammation and the renin-angiotensin system.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1257-1266
        • Griendling K.K.
        • Ushio-Fukai M.
        • Lassègue B.
        • Alexander R.W.
        Angiotensin II signaling in vascular smooth muscle: new concepts.
        Hypertension. 1997; 29: 366-373
        • Ruiz-Ortega M.
        • Ruperez M.
        • Lorenzo O.
        • et al.
        Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.
        Kidney Int Suppl. 2002; 62: S12-S22
        • Han Y.
        • Runge M.S.
        • Brasier A.R.
        Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors.
        Circ Res. 1999; 84: 695-703
        • Ruscica M.
        • Corsini A.
        • Ferri N.
        • Banach M.
        • Sirtori C.R.
        Clinical approach to the inflammatory etiology of cardiovascular diseases.
        Pharmacol Res. 2020; 159: 104916
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Higgins J.P.
        • Altman D.G.
        • Gøtzsche P.C.
        • et al.
        The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
        • Balk E.M.
        • Earley A.
        • Patel K.
        • Trikalinos T.A.
        • Dahabreh I.J.
        Empirical Assessment of Within-Arm Correlation Imputation in Trials of Continuous Outcomes.
        Agency for Healthcare Research and Quality (US), 2012
        • Follmann D.
        • Elliott P.
        • Suh I.
        • Cutler J.
        Variance imputation for overviews of clinical trials with continuous response.
        J Clin Epidemiol. 1992; 45: 769-773
      1. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality (US), 2008
        • Wan X.
        • Wang W.
        • Liu J.
        • Tong T.
        Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.
        BMC Med Res Methodol. 2014; 14: 135
        • Altman D.G.
        • Bland J.M.
        Standard deviations and standard errors.
        BMJ. 2005; 331: 903
        • Higgins J.P.
        • Thomas J.
        • Chandler J.
        • et al.
        Cochrane Handbook for Systematic Reviews of Interventions.
        Date accessed: April 5, 2022
        • Richardson M.
        • Garner P.
        • Donegan S.
        Interpretation of subgroup analyses in systematic reviews: a tutorial.
        Clin Epidemiol Global Health. 2019; 7: 192-198
        • Egger M.
        • Davey Smith G.
        • Schneider M.
        • Minder C.
        Bias in meta-analysis detected by a simple, graphical test.
        BMJ. 1997; 315: 629-634
        • Bähr I.N.
        • Tretter P.
        • Krüger J.
        • et al.
        High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.
        Hypertension. 2011; 58: 725-732
        • Biasucci L.M.
        • Lombardi M.
        • Piro M.
        • Di Giannuario G.
        • Liuzzo G.
        • Crea F.
        Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina.
        Heart. 2005; 91: 670-671
        • Ichihara A.
        • Hayashi M.
        • Kaneshiro Y.
        • et al.
        Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
        Am J Kidney Dis. 2005; 45: 866-874
        • Javanmard S.H.
        • Sonbolestan S.A.
        • Ghahdarijani K.H.
        • Saadatnia M.
        • Sonbolestan S.A.
        Enalapril improves endothelial function in patients with migraine: a randomized, double-blind, placebo-controlled trial.
        J Res Med Sci. 2011; 16: 26-32
        • Kintscher U.
        • Marx N.
        • Martus P.
        • et al.
        Effect of high-dose valsartan on inflammatory and lipid parameters in patients with type 2 diabetes and hypertension.
        Diabetes Res Clin Pract. 2010; 89: 209-215
        • Krysiak R.
        • Okopień B.
        Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease.
        Pharmacol Rep. 2008; 60: 514-523
        • Krysiak R.
        • Okopień B.
        Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
        Pharmacol Rep. 2011; 63: 1151-1161
        • Krysiak R.
        • Okopień B.
        Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure.
        Pharmacol Rep. 2012; 64: 1466-1475
        • Dessì M.
        • Piras A.
        • Madeddu C.
        • et al.
        Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction.
        Exp Ther Med. 2011; 2: 1003-1009
        • Marketou M.E.
        • Zacharis E.A.
        • Koukouraki S.
        • et al.
        Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus.
        J Hum Hypertens. 2008; 22: 191-196
        • Ordaz-Medina S.M.
        • González-Plascencia J.
        • Martín Del Campo F.
        • et al.
        Is systemic inflammation of hemodialysis patients improved with the use of enalapril? Results of a randomized, double-blinded, placebo-controlled clinical trial.
        ASAIO J. 2010; 56: 37-41
        • Perlstein T.S.
        • Henry R.R.
        • Mather K.J.
        • et al.
        Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose.
        Clin Sci (Lond). 2012; 122: 193-202
        • Ahimastos A.A.
        • Latouche C.
        • Natoli A.K.
        • Reddy-Luthmoodoo M.
        • Golledge J.
        • Kingwell B.A.
        Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.
        Circ Res. 2014; 114: 1144-1155
        • Persson F.
        • Rossing P.
        • Hovind P.
        • et al.
        Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
        Diabetes. 2006; 55: 3550-3555
        • Peters C.D.
        • Kjaergaard K.D.
        • Nielsen C.H.
        • et al.
        Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: a randomized double blind placebo controlled trial (SAFIR study).
        Hemodial Int. 2017; 21: 47-62
        • Ramadan R.
        • Dhawan S.S.
        • Binongo J.N.
        • et al.
        Effect of angiotensin II type I receptor blockade with valsartan on carotid artery atherosclerosis: a double blind randomized clinical trial comparing valsartan and placebo (EFFERVESCENT).
        Am Heart J. 2016; 174: 68-79
        • Sola S.
        • Mir M.Q.
        • Cheema F.A.
        • et al.
        Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.
        Circulation. 2005; 111: 343-348
        • Vaccari C.S.
        • Rahman S.T.
        • Khan Q.A.
        • Cheema F.A.
        • Khan B.V.
        Effects of angiotensin-converting enzyme inhibitor therapy on levels of inflammatory markers in response to exercise-induced stress: studies in the metabolic syndrome.
        J Cardiometab Syndr. 2008; 3: 12-17
        • van der Zijl N.J.
        • Serné E.H.
        • Goossens G.H.
        • et al.
        Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism.
        J Hypertens. 2011; 29: 1955-1962
        • van Haelst P.L.
        • Cohen Tervaert J.W.
        • van Geel P.P.
        • et al.
        Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1.
        Eur J Vasc Endovasc Surg. 2003; 26: 387-391
        • Verma S.
        • Lonn E.M.
        • Nanji A.
        • et al.
        Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results.
        Can J Cardiol. 2009; 25: e236-e240
        • Wassmann S.
        • Hilgers S.
        • Laufs U.
        • Böhm M.
        • Nickenig G.
        Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1208-1212
        • White M.
        • Lepage S.
        • Lavoie J.
        • et al.
        Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
        J Card Fail. 2007; 13: 86-94
        • Bank A.J.
        • Kelly A.S.
        • Kaiser D.R.
        • et al.
        The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
        Vasc Med. 2006; 11: 251-257
        • Link A.
        • Lenz M.
        • Legner D.
        • Böhm M.
        • Nickenig G.
        Telmisartan inhibits β2-integrin MAC-1 expression in human T-lymphocytes.
        J Hypertens. 2006; 24: 1891-1898
        • Mostafa T.
        • Hegazy S.
        • Elshebini E.
        • Saif D.
        • Elabd A.
        A comparative study on the anti-inflammatory effect of angiotensin-receptor blockers & statins on rheumatoid arthritis disease activity.
        Indian J Med Res. 2020; 152: 393-400
        • Bohm F.
        • Beltran E.
        • Pernow J.
        Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition.
        J Intern Med. 2005; 257: 263-271
        • Ceconi C.
        • Fox K.M.
        • Remme W.J.
        • et al.
        ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study.
        Atherosclerosis. 2009; 204: 273-275
        • Fan X.
        • Copeland P.
        • Nawras S.
        • et al.
        Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.
        Psychopharmacology (Berl). 2019; 236: 1949-1957
        • Fernandez M.
        • Triplitt C.
        • Wajcberg E.
        • et al.
        Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
        Diabetes Care. 2008; 31: 121-127
        • Gibas M.
        • Miszczak-Śmiałek J.
        • Madry E.
        • Głuszek J.
        • Witmanowski H.
        • Piotrowski J.
        Influence of preventive therapy with quinapril on IL-6 level in patients with chronic stable angina.
        Pharmacol Rep. 2007; 59: 330-338
        • Goossens G.H.
        • Moors C.C.
        • van der Zijl N.J.
        • et al.
        Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial.
        PLoS One. 2012; 7: e39930
        • Golia E.
        • Limongelli G.
        • Natale F.
        • et al.
        Inflammation and cardiovascular disease: from pathogenesis to therapeutic target.
        Curr Atheroscler Rep. 2014; 16: 435
        • Gallino A.
        • Aboyans V.
        • Diehm C.
        • et al.
        Non-coronary atherosclerosis.
        Eur Heart J. 2014; 35: 1112-1119
        • Ferrario C.M.
        • Strawn W.B.
        Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.
        Am J Cardiol. 2006; 98: 121-128
        • Kranzhöfer R.
        • Schmidt J.
        • Pfeiffer C.A.
        • Hagl S.
        • Libby P.
        • Kübler W.
        Angiotensin induces inflammatory activation of human vascular smooth muscle cells.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1623-1629
        • Hahn A.W.
        • Jonas U.
        • Bühler F.R.
        • Resink T.J.
        Activation of human peripheral monocytes by angiotensin II.
        FEBS Lett. 1994; 347: 178-180
        • Chen X.L.
        • Tummala P.E.
        • Olbrych M.T.
        • Alexander R.W.
        • Medford R.M.
        Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.
        Circ Res. 1998; 83: 952-959
        • Morawietz H.
        • Rueckschloss U.
        • Niemann B.
        • et al.
        Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.
        Circulation. 1999; 100: 899-902
        • Montecucco F.
        • Pende A.
        • Mach F.
        The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.
        Mediators Inflamm. 2009; 2009: 752406
        • Mason R.P.
        Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
        Cardiovasc Ther Prev. 2012; 11: 102-112
        • Gainer J.V.
        • Morrow J.D.
        • Loveland A.
        • King D.J.
        • Brown N.J.
        Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
        N Engl J Med. 1998; 339: 1285-1292
        • Vanhoutte P.M.
        Endothelium and control of vascular function. State of the art lecture.
        Hypertension. 1989; 13: 658-667
        • Murphey L.J.
        • Malave H.A.
        • Petro J.
        • et al.
        Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.
        J Pharmacol Exp Ther. 2006; 318: 1287-1292
        • Bots M.L.
        • Remme W.J.
        • Lüscher T.F.
        • et al.
        ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
        Cardiovasc Drugs Ther. 2007; 21: 269-279
        • Hornig B.
        • Kohler C.
        • Drexler H.
        Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.
        Circulation. 1997; 95: 1115-1118
        • Ancion A.
        • Tridetti J.
        • Nguyen Trung M.L.
        • Oury C.
        • Lancellotti P.
        A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril.
        Cardiol Ther. 2019; 8: 179-191
        • Taddei S.
        • Bortolotto L.
        Unraveling the pivotal role of bradykinin in ACE inhibitor activity.
        Am J Cardiovasc Drugs. 2016; 16: 309-321
        • Yeh C.H.
        • Chen T.P.
        • Wang Y.C.
        • Lin Y.M.
        • Fang S.W.
        Cardiomyocytic apoptosis limited by bradykinin via restoration of nitric oxide after cardioplegic arrest.
        J Surg Res. 2010; 163: e1-e9
        • Gilbert K.C.
        • Brown N.J.
        Aldosterone and inflammation.
        Curr Opin Endocrinol Diabetes Obes. 2010; 17: 199-204
        • Markan U.
        • Pasupuleti S.
        • Pollard C.M.
        • Perez A.
        • Aukszi B.
        • Lymperopoulos A.
        The place of ARBs in heart failure therapy: is aldosterone suppression the key?.
        Ther Adv Cardiovasc Dis. 2019; 13 (1753944719868134)
        • Tsikouris J.P.
        • Suarez J.A.
        • Simoni J.S.
        • Ziska M.
        • Meyerrose G.E.
        Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction.
        Coron Artery Dis. 2004; 15: 211-217
        • Shakour N.
        • Ruscica M.
        • Hadizadeh F.
        • et al.
        Statins and C-reactive protein: in silico evidence on direct interaction.
        Arch Med Sci. 2020; 16: 1432-1439
        • Bytyçi I.
        • Bajraktari G.
        • Penson P.E.
        • et al.
        Efficacy and safety of colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
        Br J Clin Pharmacol. 2022; 88: 1520-1528
        • Ruscica M.
        • Penson P.E.
        • Ferri N.
        • et al.
        Impact of nutraceuticals on markers of systemic inflammation: potential relevance to cardiovascular diseases—a position paper from the International Lipid Expert Panel (ILEP).
        Prog Cardiovasc Dis. 2021; 67: 40-52
        • Takagi H.
        • Yamamoto H.
        • Iwata K.
        • Goto S.N.
        • Umemoto T.
        Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials.
        Int J Cardiol. 2012; 156: 238-241
        • Banach M.
        • Penson P.E.
        Colchicine and cardiovascular outcomes: a critical appraisal of recent studies.
        Curr Atheroscler Rep. 2021; 23: 32
        • Visseren F.L.
        • Mach F.
        • Smulders Y.M.
        • et al.
        2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
        Eur Heart J. 2021; 42: 3227-3337
        • Crews D.C.
        • Sozio S.M.
        • Liu Y.
        • Coresh J.
        • Powe N.R.
        Inflammation and the paradox of racial differences in dialysis survival.
        J Am Soc Nephrol. 2011; 22: 2279-2286
        • Noori N.
        • Kovesdy C.P.
        • Dukkipati R.
        • et al.
        Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation.
        Am J Nephrol. 2011; 33: 157-167

      Linked Article

      • Making a Case for the Anti-inflammatory Effects of ACE Inhibitors and Angiotensin II Receptor Blockers: Evidence From Randomized Controlled Trials
        Mayo Clinic ProceedingsVol. 97Issue 10
        • Preview
          In this issue of Mayo Clinic Proceedings, Awad and colleagues1 present a meta-analysis of randomized controlled trials evaluating the effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) as anti-inflammatory agents. Their findings support the beneficial role of ACEIs and ARBs in reducing blood levels of inflammatory markers but reveal potential differences in their anti-inflammatory effects. However, regardless of the class of medications used, the implications of the results merit the need to better understand the inflammation-alleviating effects of renin-angiotensin-aldosterone system (RAAS) inhibition.
        • Full-Text
        • PDF